The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients

Endocrine Research

Volumn 30, Issue 3, 2004, Pages 343-349

  Coban, Erkan ^a   Sari, Ramazan ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Anti inflammatory effect; C reactive protein; Fenofibrate; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; FENOFIBRATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; METABOLIC PARAMETERS; OBESITY; PRIORITY JOURNAL;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTILIPEMIC AGENTS; C-REACTIVE PROTEIN; CHOLESTEROL; FEMALE; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MIDDLE AGED; OBESITY; PROCETOFEN; REFERENCE VALUES; TRIGLYCERIDES;

EID: 7544221725     PISSN: 07435800     EISSN: None     Source Type: Journal    
DOI: 10.1081/ERC-200033541     Document Type: Article

References (27)

1. Benzaquen LR, Yu H, Rifai N. High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment. Crit Rev Clin Lab Sci 2002; 39:459-497.
2. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112:1785-1788.
3. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002; 252:283-294.
4. Ridker PM. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view. Blood Coagul Fibrinolysis 1999; 10:S9-S12.
5. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003; 92:17K-22K.
6. Futterman LG, Lemberg L. High sensitivity C-reactive protein is the most effective prognostic measurement of acute coronary events. Am J Crit Care 2002; 11:482-486.
7. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001; 47:403-411.
8. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 2003; 107:391-397.
9. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 2003; 170:315-323.
10. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRHLT nested case-control study. Multiple risk factor intervention trial. Am J Epidemiol 1996; 144:537-547.
11. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project. Arterioscler Thromb Vasc Biol 1997; 17:1121-1127.
12. Winegar DA, Brown PJ, Wilkison WO, Lewis MC, Ott RJ, Tong WO, Brown HR, Lehmann JM, Kliewer SA, Plunket KD, Way JM, Bodkin NL, Hansen BC. Effects of fenofibrate on lipid parameters in obese rhesus monkeys. J Lipid Res 2001; 42:1543-1551.
13. Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med 2000; 247:563-569.
14. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, Rees A. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000; 18(101):1773-1779.
15. Watts GF, Dimmitt SB. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 1999; 10:561-574.
16. Rizos E, Kostoula A, Elisaf M, Mikhailidis DP. Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology 2002; 53:273-277.
17. Baron RB. Lipid abnormalities. In: Tiernay LM, McPce SJ, Papadakus MA, eds. Current Medical Diagnosis and Treatment. 40th ed. New York: McGraw-Hill, Lange Medical Books, 2001:1208-1221.
18. Ferrannini E, Haffner SM, Mitchell BD, Stem MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34:416-422.
19. Vidal H. Obesity and inflammation: the adipocytokines. Ann Endocrinol (Paris) 2003; 64:S40-S44.
20. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97:2007-2011.
21. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98:2088-2093.
22. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002; 18:269-276.
23. Zhao SP, Ye HJ, Zhou HN, Nie S, Li QZ. Gemfibrozil reduces release of tumor necrosis factor-alpha in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease. Clin Chim Acta 2003; 332:61-67.
24. Chen YE, Fu M, Zhang J, Zhu X, Lin Y, Akinbami MA, Song Q. Peroxisome proliferator-activated receptors and the cardiovascular system. Vitam Horm 2003; 66:157-188.
25. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPAR gamma activators. Nature 1998; 393:790-793.
26. Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MC, Hong SH, Hwang TH, Kang DY, Garber AJ, Kim DK. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophys Res Commun 2002; 296:293-299.
27. Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wojcik J, Zarnecki A, Blane G. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 2000; 30:871-878.